NewLink Genetics To Present New Data from Phase 1b Study

NewLink Genetics (NASDAQ:NLNK) shared new data from a Phase 1b study of indoximod combined with other parts for patients with newly diagnosed acute myeloid leukemia.
As quoted in the press release:

These data indicate indoximod does not appear to add significant toxicity to standard therapy for patients with newly diagnosed AML, and no regimen-limiting toxicities (RLT) have been observed to date. Initial data show that the morphological complete remission (CR) rate is as expected after one cycle of induction chemotherapy.  Seven of seven patients who achieved CR were found to have no minimal residual disease (MRD-neg).
“While from a small number of patients, these data show an encouraging MRD negativity rate and may offer the potential for measurable clinical benefits for patients,” said Dr. Emadi, Principal Investigator of this study.

Click here to read the full press release.

Source: globenewswire.com